VEGFA and breast carcinoma: In only one case was a provisional approval for a breast cancer drug subsequently withdrawn: after initial approvals in colorectal and non-small cell lung cancer, the FDA had granted the VEGF inhibitor bevacizumab accelerated approval for breast cancer in February 2008, while demanding additional data “to further define the degree of clinical benefit”.